Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
DBV Technologies SA – American ( (DBVT) ) has provided an update.
On June 25, 2025, DBV Technologies announced the screening of the first subject in their COMFORT Toddlers supplemental safety study, which targets peanut-allergic toddlers aged 1 to 3 years. The study, involving approximately 480 subjects across multiple countries, aims to supplement safety and efficacy data for the Viaskin Peanut patch. This development marks a significant step towards potentially advancing the Viaskin Peanut patch to market, with data supporting a Biologics License Application submission anticipated in the second half of 2026 under the FDA’s Accelerated Approval Pathway. The initiation of this study underscores DBV Technologies’ commitment to addressing the unmet needs of food allergic patients.
The most recent analyst rating on (DBVT) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on DBV Technologies SA – American stock, see the DBVT Stock Forecast page.
Spark’s Take on DBVT Stock
According to Spark, TipRanks’ AI Analyst, DBVT is a Neutral.
The overall stock score for DBV Technologies SA is driven by financial instability and unfavorable valuation metrics. However, recent significant financing for the Viaskin Peanut program positively impacts the score, indicating potential growth opportunities despite existing challenges.
To see Spark’s full report on DBVT stock, click here.
More about DBV Technologies SA – American
DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions. The company is currently investigating the use of its proprietary VIASKIN® patch technology, which introduces microgram amounts of a biologically active compound to the immune system through intact skin, aiming to desensitize individuals to allergens. DBV Technologies is headquartered in Châtillon, France, with operations in North America, and its shares are traded on Euronext Paris and Nasdaq.
Average Trading Volume: 442,108
Technical Sentiment Signal: Buy
Current Market Cap: $238.8M
For an in-depth examination of DBVT stock, go to TipRanks’ Overview page.